PURA Rated BULLISH Following News with KALY on 1st Shipment of $1 Million Order

Screen Shot 2018-12-14 at 11.04.10 AM.png

New York, NY – November 14, 2018 - Puration, Inc. (PURA) is rated BULLISH today by BullishInvestor.com after the company yesterday announced with Kali, Inc. (KALY) the first shipment of a private label CBD infused water with a custom extract from KALY.

Kali-Extracts and Puration Announce First Shipment Of Hemp-Derived CBD Infused Private Label Water For Pharmaceutical Client

Screen Shot 2018-12-13 at 10.36.21 PM.png

From the PURA and KALY News

“… announced shipping the first private labeled, hemp-derived CBD infused, high alkaline water to Generex Biotechnology Corporation (OTCQB: GNBT) in conjunction with a previously announced agreement to produce $1 million of CBD infused water for Generex.  PURA is producing the CBD infused water for Generex and PURA has in turn engaged KALY in a $300,000 contract to produce the CBD extract specific to the requirements of Generex. 

KALY and HEMP Positioned To Benefit From $867 Billion Farm Bill

After Congress passed the $867 Billion Farm Bill legalizing hemp farming, KALY and Hemp, Inc. (HEMP) were both found on the OTCMarkets top 10 most active traders by share volume list. KALY is on the list again today, though HEMP has slipped down slightly while still in the top 20.  Another company benefiting from the Farm Bill that hs moved up today’s top 10 list is USMJ.  The large trading volumes at these levels is a reasonable indication that a base is building for bigger gains.

Screen Shot 2018-12-14 at 11.00.57 AM.png

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

KALY Rated a BUY with PPS up 60% to $0.005 Heading To $0.01 Potential Breakout

American Bulls Logo and KALY.jpg

New York, NY – December 12, 2018 Kali, Inc. (USOTC: KALY) was recommended as a BUY today by AmericanBulls.com.  The KALY PPS has advanced over 60% so far this week on high trading volume.  KALY has been one of the top 50 most actively traded stocks on OTCMarkets for two straight days reaching over $100,000 in trading volume on Monday and over $200,000 in trading volume on Tuesday. On November 1st, the KALY PPS tested a $0.01 breakthrough on news of a LOI to acquire a patented cannabis extraction process.  KALY has since closed the acquisition and announced $300,000 contract to extract hemp-derived CBD, and plans to introduce its own hemp-derived CBD gum before the end of the year.  The company has indicated its intentions to have all public information current on the OTCMarkets soon.  KALY’s acquisition and sales progress is positioned for a boost from developments in the overall hemp-derived CBD market with the pending legalization of hemp anticipated in the 2018 Farm Act now approved by the Senate and expected to be signed into law by President Trump before the end of the month.  KALY momentum is building and the PPS is currently out performing other cannabis stock leaders like Hemp, Inc. (HEMP), Pot Networks (POTN) and Cannabis Science (CBIS).  KALY momentum continues to build and now with the patented cannabis extraction asset on its balance sheet and generating revenue, the KALY PPS looks on track to soon be trading over $0.01

Screen Shot 2018-12-12 at 7.21.01 AM.png

AmericanBulls.com

“Our system’s recommendation today is to BUY. The BULLISH ONE WHITE SOLDIERpattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0039, and our valid average buying price stands now at 0.0040.”

“Let’s jump on our white horses and go for a bullish ride. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. The market is telling you about a new profit. Do not miss this bullish opportunity.”  

Learn more at www.kali-extracts.com.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

 

KALY Trading At $0.004 On High Volume Above 50 Day MA With Potential To Break $0.01

KALY LOGO.jpg

New York, NY – December 11, 2018 Kali, Inc. (USOTC: KALY) today is one of the top 50 most actively traded stocks on OTCMarkets along with Hemp, Inc. (HEMP), North American Cannabis Holdings, Inc. (USMJ) and Hemp America, Inc. (HMPQ).  The KALY PPS moved up 30% yesterday on over $100,000 of trading volume and the PPS is up again today.  KALY continues to be rated VERY BULLISH by Stockta.com.  KALY is trading above its 200, 100, and 50 Day Moving Averages. Just over 30 days ago, in the midst of the Canadian recreational marijuana legalization market surge, KALY hit a high of $0.009 pushing the penny boundary.  Since then, KALY has acquired a patented cannabis extraction process and the associated pharmaceutical research that came with the patent, additionally  announcing a $300,000 contract to extract hemp-derived CBD, and plans to introduce its own hemp-derived CBD gum before the end of the year.  The company has recently begun updating the new post patent acquisition information on OTCMarkets and has indicated its intentions to have all public information on the OTCMarkets updated soon.  With the newly acquired patented cannabis extraction asset, a signed $300,000 contract, the production of its own CBD infused product underway, and updated public disclosures, all combined with the pending legalization of hemp farming included in the 2018 Farm Act signed by Senator Mitch McConnell yesterday (using a hemp pen), KALY looks poised to break through the $0.01 before the end of the year.

KALY Chart DEC 11.png

90 days ago, KALY’s PPS was lingering on low volume between $0.0003 by $0.0004.  In mid-October, KALY trading came to life when the company announced an LOI to acquire the patented cannabis extraction process.  All total, in the last 90 days, the trading volume has turned over the issued and outstanding almost five times at a weighted average PPS of just under $0.003 reaching a high of $0.009 on November 1st.  Since the market cooling off following the Canadian recreational marijuana legalization market surge, KALY trading has hovered around the $0.003 90 day weighted average.  Yesterday, after KALY announced its $300,000 hemp-derived CBD extraction contract, the PPS started to move north. As the cannabis market heats up in conjunction with the U.S. anticipated legalization of hemp farming as drafted into the pending 2018 Farm Act, KALY is staged, both business development wise and stock technical wise, to realize a substantial PPS climb.

Learn more at www.kali-extracts.com.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

KALY Rated VERY BULLISH with PPS up 30% on High Volume After $300K CBD Extract Contract Announcement

New York, NY – December 10, 2018 Kali, Inc. (USOTC: KALY) is rated VERY BULLISH today by Stockta.com after the company announced a $300,000 contract to extract hemp-derived CBD.  The PPS is up over 30% and KALY trading volume is in the top 50 most actively traded stocks on OTCMarkets.

Screen Shot 2018-12-10 at 12.54.48 PM.png

“With the legalization of hemp farming on the near horizon as drafted into the pending 2018 Farm Act, the flood gates are about to open for Kali-Extracts,” Said Frederick Ferri, the founder of NCM Biotech, and the incoming CEO of Kali-Extracts. “I am already receiving daily inquiries to formulate custom hemp-derived CBD extractions.  The pending legalization of hemp farming, combined with the recent DEA removal of CBD from schedule 1, is igniting the commercialization of hemp-derived CBD concentrates for a multitude of applications from pharmaceutical to sports nutrition to over the counter pain management to general health and wellness.”

Learn more about NCM Biotech at www.kali-extracts.com.

Other cannabis companies in the top 50 most actively traded on the OTCMarkets today include North American Cannabis Holdings, Inc. (USMJ), HEMP, In.c (HEMP), and Enviro-Serv (EVSV).

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

 

Source: www.nextbigticker.com

 

 

 

 

GNBT ALERT – PPS Could Break 52 Week $25 High As Apex Clearing Firm Buys Back Phantom GNBT Stock Mistakenly Issued In Tech Glitch

New York, NY – November 23, 2018 – Generex Biotechnology Corp (OTCQB: GNBT) issued an announcement on Wednesday this week to warn shareholders that Apex Clearing Firm had mistakenly issued phantom GNBT stock.  Sales of the phantom stock were the likely cause of a GNBT PPS decline on Wednesday.  Any sale of the phantom stock is effectively a short sale and Apex will be required to purchase shares to cover such short sales.  All short sales will have to be covered with the purchase of stock within three trading days.  The APEX buy back could trigger a GNBT run back to the recent 52 week high of $25.  GNBT has been very active of late with major acquisitions and the initiation of clinical trials.  The combination of positive GNBT news and the APEX buy back could give investors a substantial ROI.

Generex is currently a quiet giant of a pharmaceutical company that most people probably are not yet aware even exists.  Do a little research and you will find Generex is loaded with proprietary, intellectual property protected pharmaceutical technology. 

Learn more about Generex at http://www.generex.com/

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

PURA ALERT – BUY Recommendation Issued Following Research Coverage Update With $0.25 PPS Target Confirmation

New York, NY – November 20, 2018 - Puration, Inc. (PURA) received a BUY recommendation from AmericBulls.com after the Goldman Small Cap Research yesterday released an update to its ongoing research coverage of PURA that confirmed a Speculative BUY and $0.25 PPS Target PPS.

Screen Shot 2018-11-21 at 7.21.40 AM.png

Americanbulls.com:

“Our system’s recommendation today is to BUY. The BULLISH STOP LOSS pattern finally received a confirmation because the prices crossed above the Stop Loss level which was at 0.1089, and our valid average buying price stands now at 0.1091.

A rally after a bear setup can occasionally turn into an explosive long trade. We may be on the verge of catching one of them. There is now a strong positive sentiment in the market despite the absence of a bullish pattern. The bullish stop loss is finally confirmed, and a BUY signal is generated. The Market wants to reward the bulls. It may be the right time to be part of this boost and bullish market sentiment by joining the growing bullish crowd.”

Goldman Small Cap Research:

“PURA announced very strong 3Q18 results and the best is yet to come. As a result, we believe that current prices represent a terrific entry point for opportunistic investors. Moreover, we expect PURA could return to its 52-week high of $0.25 early next year, on the heels of products with new, upgraded packaging which will begin reaching stores next week. PURA’s new package form is priced at a convenient $20 per 4-pack. Management believes that this new form will take sales to the next level.

We believe our forecasts are conservative. For 2019, we estimate sales will reach $3M, with operating profit of $800,000. It should be noted that these figures exclude any contributions from new products which are likely to be introduced in the coming weeks. Separately, an under the radar near-term catalyst is the pending dividend related to the transaction with Nouveau Life Pharmaceuticals, (OTC - NOUV). NOUV formally declared a 1:5 stock dividend whereby NOUV common will be issued to PURA shareholders at a ratio of one NOUV common share for every five shares of PURA held on the yet to be determined date of record.  Although this event is not factored into the current stock price, we believe these shares could rise ahead of the record date announcement.“

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

 

KALY – Green Lighted and Recommended as Screaming “BUY” Following Patented Cannabis Extraction Acquisition

New York, NY – November 16, 2018 Kali, Inc. (USOTC: KALY) is recommended as a “BUY” today by AmericBulls.com following yesterday’s announcement that KALY had finalized the acquisition of NCM Biotech, the developer and owner of a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”  The KALY news reported the company plans to leverage the patent to enter the cannabis pharmaceuticals and concentrates market.  The news yesterday further reported that the cannabis pharmaceuticals market is forecasted to reach $50 billion in sales by 2029, and that the cannabis concentrates for wellness, edibles and recreational markets is forecasted to reach $8.5 billion in annual sales by 2022.

AmericanBulls.com:

“Our system’s recommendation today is to BUY. The BULLISH HARAMI pattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0038, and our valid average buying price stands now at 0.0039 …

The green light is on and this security is now screaming BUY. It is action time! The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. Do not miss this bullish opportunity.” 

Screen Shot 2018-11-16 at 7.38.38 AM.png

KALY’s news yesterday included more information on the company’s plans to expand with a differentiated service in the cannabis pharmaceuticals and concentrates sector.  “Kali, with its recent acquisition of NCM Biotech, has separately announced entering into a joint venture (JV) company called US Cannabis Health with Puration [PURA] and Nouveau life Pharmaceuticals (USOTC: NOUV).”

Notably, the news yesterday emphasized that KALY had no plans for a reverse split in conjunction with the patented cannabis extraction acquisition.

In reference to what all comes with the acquisition, KALY’s news yesterday included the following:

“NCM Biotech’s current research and ongoing pharmaceutical developments come with the acquisition.  Commenting on the research NCM Biotech has undertaken with notable medical institutions in the North East, Frederick Ferri, CEO and Founder of NCM Biotech said, “Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical [GWPH] products and candidate products. “ “

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

 

EVSV - Enviro-Serv Rated VERY BULLISH on Cannabis News and Florida Election Prospects

New York, NY – October 30, 2018 – Enviro-Serv Inc. (USOTC: EVSV) continues with a VERY BULLISH rating based on candle stick analysis after the company announced plans to enter the cannabis sector as as service provider to hemp farmers. The company has hinted at a pending strategic announcement with a recognized cannabis sector company coming soon. Being headquartered in Florida, the midterm election results today could have a positive impact on the company’s cannabis sector plans with more pro legal marijuana elected officials coming into office.

Screen Shot 2018-11-06 at 9.03.27 AM.png

“The stock price direction for the day for EVSV is UP. The stock is experiencing a strong uptrend as of late … Based on BullishInvestor.com’s proprietary algorithms, EVSV is currently signaling VERY BULLISH.

… Overall the technical indicators are signaling a bullish reading for EVSV. As such, it may be a wise decision to consider EVSV at these price levels …

Since the stock is currently rated VERY BULLISH, investors are encouraged to take a closer look at this stock from a technical analysis perspective.”

NextBigTicker.com has also recently featured West Coast Venture Group, Corp (WCVC), Puration, Inc. (PURA) and Optec International (OPTI).

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

LDSR’s Data443 Headlines with Microsoft and Facebook In BIGToken Feature On $124 Billion Data Privacy Market

New York, NY – November 6, 2018 - LandStar, Inc. (OTCPK: LDSR), the parent company of Data443™ Risk Mitigation, Inc. (“Data443”), a leading data security and privacy company, is featured in a release from BIGToken, a consumer Blockchain platform.  The BIGToken feature was released yesterday addressing the burgeoning Data Privacy market.  The feature includes quotes from Facebook (NASDAQ: FB) CEO Mark Zuckerberg, Microsoft (NASDAQ: MSFT) CEO Satya Nadella, Jason Remillard, CEO and founder of LDSR’s Data443.  The article is included below, in addition to a link to the original article.  The article has been republished here to emphasize the as of yet undiscovered LDSR opportunity.  LDSR closed yesterday at $0.005 at the same time it was featured in an article with Microsoft and Facebook.  Recent analyst coverage recommended LDSR at a Speculative BUY with a $0.027 Target PPSWith LDSR being featured by the Data Privacy industry side by side with Micrsoft and Facebook, it appears that LDSR is undervalued and that even the over 400% ROI that would be realized at the $0.027 Target PPS, might not adequately represent LDSR’s underlying value.

Big Token.png

BIGtoken Team -The blockchain platform for consumers to own, verify, and sell their data.

Nov 5

Microsoft CEO Says Data Privacy is a Human Right: The Week in Data Privacy and Transparency

In this week’s data privacy news, the CEO of Microsoft urges tech companies to focus on data privacy, Mark Zuckerberg announces Facebook’s data privacy timeline, Data443 releases an innovative data security product, and more.

Laptop Image.png

Microsoft CEO Satya Nadella speaks out about data privacy

In a keynote address this past Thursday, Nadella voiced his support for privacy as a “human right.” He focused on three major elements: privacy, cybersecurity and AI ethics. He cited EU’s General Data Protection Regulation (GDPR) as a model form of legislation. This nod follows a similar sentiment from Apple CEO Tim Cook, who championed the legislation at a talk this month as well. Nadella urged companies to see common citizens and small businesses as the most vulnerable to cyber threats, and tasked them with using their power to protect them.

“We need to use our collective prowess and power to protect these most vulnerable of populations, and it requires not just our industry but also nation states to be part of that,” he said. His final note touched on the importance of regulating AI as the impressive technology continues to develop. The need for ethical standards around artificial intelligence is becoming dire, and it’s the responsibility of massive tech companies like Microsoft and Apple to reckon with the consequences of this innovation.

Mark Zuckerberg sees major privacy updates coming in 2019

In a third-quarter earnings call with analysts, Facebook CEO Mark Zuckerberg reportedly claimed that some much-needed privacy updates are coming in 2019. “A few years ago, Facebook was very behind where it needed to be,” Zuckerberg said. “We started a three-year roadmap through the end of 2019 to get our systems to the level where we think we should be at — systems that can flag information that we think might be problematic to a much larger security and review team.” He went on: “But we are up against sophisticated adversaries and threats will continue to evolve.” He reassured them by saying that the company is getting better and better at detecting threats and eliminating them.

More specifically, Zuckerberg claimed that the platform has flagged several groups from Russia and Iran who have been using social media to sway elections and encourage political and social divisions in the U.S., the UK and elsewhere. But he cited the massive growth of Facebook users as the key issue moving forward. Facebook had 2.27 billion monthly average users in September. It’s estimated that more than 2.6 billion people now use Facebook, WhatsApp, Instagram, or Messenger each month.

Zucherburg.png

New security product from Data443 is a major step forward

Data443 released version 1.43 of ClassiDocs last week, which is a huge advancement for data privacy tech and GDPR compliance. The system uses a Data Repository Owner Identification technology to securely manage data, and help businesses comply with GDPR in a number of ways. “Data privacy and GDPR response continue to drive IT spending worldwide,” said Jason Remillard, founder of Data443. “And these factors are just as important if not more so for the vast number of companies that use cloud services to manage and conduct their business. Our mission has always been to deliver industry-leading cybersecurity products that empower organizations to solve real-life data challenges.”

Companies are expected to spend $124 billion worldwide on information security products and services in 2019, and a large portion of that spending is to ensure GDPR compliance. And as cloud services become more and more popular, that market increases to an estimated $300 billion-plus by 2021. The adoption of cloud services is the way of the future, but it increases the need for sophisticated security. The newest version of ClassiDocs is certainly one of the most comprehensive solutions to the problem yet.


Republished by NextBigTicker.com

NextBigTicker.com has also recently featured Puration, Inc. (PURA), North American Cannabis Holdings, Inc. (USMJ) and Alternet Systems, Inc. (ALYI).

Full Article Source: https://medium.com/bigtoken/microsoft-ceo-says-data-privacy-is-a-human-right-the-week-in-data-privacy-and-transparency-27cddbaba0e1

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

GNBT - Goldman Small Cap Research Initiates Generex Coverage With $40 Target PPS Pre-Dividend

Goldman Small Cap Research - November 5, 2018

Every once in a while, we see an unusual situation and write about it to alert you to it. Today is one of those days. Normally idea would not be of a diversified health care stock that went from $2 to $25 (before settling back) in about a month. But, in this situation, there are interesting circumstances regarding a big stock dividend and an aggressive M&A strategy to match its R&D pipeline. News about an unusual dividend came out this morning and prompted this email. Against this backdrop, we issued a research report and an interview with the CEO this morning. Let me introduce it to you…

FAST FACTS

  • Almost overnight, Generex Biotechnology (OTC – GNBT) could go from also-ran to a firm generating revenue at an annual run-rate of hundreds of millions annually. The Company just closed on an acquisition that has generated $100M or more annually in recent years and is primed to grow dramatically as it begins to offer its services in 30 states, versus 3 this year.

  • There are more deals in the pipeline. Generex plans to become a diversified health care firm that utilizes cash from its high growth M&A targets to help fund its R&D in the areas where an unmet need exists. These include diabetes, breast cancer, prostate cancer and others.

  • The Company is collaborating with a Canopy Growth-invested firm to explore using one of its delivery system offerings for medical marijuana patients in Canada.

  • Generex announced a 20:1 stock dividend with a record date of Friday (which means investors must own the stock by Tuesday or Wednesday to be eligible to receive it). While there is likely to be a re-adjustment in share price as a result, the current market capitalization, compared with its likely revenue next year (via M&A) and underlying value of its portfolio, appears to be at a major discount.

The recent Generex Biotechnology (OTC – GNBT) Research Report is included below:

GNBT-11.5.18-[2]_Page_01.jpg
GNBT-11.5.18-[2]_Page_02.jpg
GNBT-11.5.18-[2]_Page_03.jpg
GNBT-11.5.18-[2]_Page_04.jpg
GNBT-11.5.18-[2]_Page_05.jpg
GNBT-11.5.18-[2]_Page_06.jpg
GNBT-11.5.18-[2]_Page_07.jpg
GNBT-11.5.18-[2]_Page_08.jpg
GNBT-11.5.18-[2]_Page_09.jpg
GNBT-11.5.18-[2]_Page_10.jpg

Source: http://www.goldmanresearch.com/201811051217/Opportunity-Research/new-interview-with-gnbt-ceo-and-a-new-research-report.html

OPTI – OPTEC International Inc Offers Proven Green Energy Solution In $700 Billion Market Segment

OPTI LOGO.jpg

New York, NY – November 5, 2018 – OPTEC International, Inc. (OTCQB) is, so far, a quiet little green energy firm producing an emissions reducing device built on a proven patented technology. The company is likely to become a recognized brand name in the near future.  OPTEC entered the market this past summer when it acquired rights to the emission reducing technology for the international market.  The OPTEC technology is packaged into a device that can be fitted onto a gasoline or diesel engine to improve fuel efficiency and reduce emissions.  Savings from reduced fuel consumption makes emissions reduction actually cost effective.  The OPTEC Fuel Maximizer works on personal transportation and is ideal for truck fleets.  The global automotive aftermarket sector size in 2016 was over $640 billion and is expected to reach over $722 billion by 2020. The technology is also applicable to generators producing electricity opening another entire market opportunity for OPTEC’s green energy solution. 

Green energy solutions that reduce harmful carbon emissions from existing petroleum powerplants is an underappreciated, but essential market segment.  The transition to electric powered transportation or other alternative fuel solutions is years away and in the meantime, carbon emissions reduction relies on improving the efficiency of existing petroleum fuel burning powerplants. OPTEC is a standout in this underappreciated market that will soon come to the market’s attention as endeavors like Tesla (NADAQ: TSLA) continue to run into roadblocks and setbacks.

$5.00 PPS Quick Double Potential

At $5.00 PPS with a 52-week high of $10.40 and only 3.2 million shares in the float, OPTEC presents an attractive opportunity for a quick double as the company’s practical green energy solution gains market awareness.

OPTEC Fuel Maximizer

The product is a small, non-intrusive system that connects to an engines fuse box and source of vacuum. It requires no tanks or water reservoirs. By definition the Optimized Fuel Maximizer is a hydrogen fuel cell and it’s function is to emit a micro amount of hydrogen and cooler air into the combustion chamber to complete the combustion of the fuel. The technology is fully patented by the manufacturer and has undergone rigorous third-party testing to support performance claims and engine safety.

Screen Shot 2018-11-05 at 6.57.37 AM.png

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

GNBT Rated BUY After Setting Dividend Record Date Of Nov 5 and Announcing Partnership With Canopy Growth Backed HydRx Farms

New York, NY – October 31, 2018 – Generex Biotechnology Corp (OTCQB: GNBT) stock has been rated a BUY based on candle stick analysis. The rating comes after the company announced a 20:1 for one dividend record date of Monday, November 5th, 2018 with a rapid payment date the next week on November 13th.  Generex became a prominent new player in the cannabis pharmaceutical sector recently when the company  announced a deal with HydRx Farms Ltd. which is more commonly known by its operating name, Scientus Pharma.  Scientus is backed by Canopy Growth (NYSE: CGC).  The BUY rating was issued before the Generex BREAKING NEWS just published this morning on the company’s acquisition of the remaining assets Vento Holding.

Screen Shot 2018-11-02 at 7.17.51 AM.png

 “Our system’s recommendation today is to BUY. The BULLISH ONE WHITE SOLDIER pattern finally received a confirmation because the prices crossed above the confirmation level which was at 9.9500, and our valid average buying price stands now at 10.0150. 

The green light is on and this security is now screaming BUY. It is action time! The bullish pattern that was previously identified is finally confirmed and a BUYsignal is generated. Most probably, it is the right time to participate in bullish fervor. Do not miss this bullish opportunity”

AmericanBulls.com

See our previous release on Generex from earlier this week:

Generex Enters $50 Billion Cannabis Pharmaceuticals Sector With Canopy Growth Backed Partner

Learn more about Generex at http://www.generex.com/

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. 

Source: www.nextbigticker.com

 

 

GNBT – Generex Enters $50 Billion Cannabis Pharmaceuticals Sector With Canopy Growth Backed Partner

SC+CG=GNBT.jpg

New York, NY – October 31, 2018 – Generex Biotechnology Corp (OTCQB: GNBT) today announced a deal with HydRx Farms Ltd. which is more commonly known by its operating name, Scientus Pharma.  Scientus is backed by none other than Canopy Growth (NYSE: CGC). Check out the bottom of page 5 of Canopy Growth’s Management Discussion & Analysis found on Canopy’s website to see their 9.9% HydRx ownership. Generex, by itself is no slouch.  Generex, separate from Scientus and Canopy, has just filed an investigational new drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate Phase II Clinical Trials of a vaccine for patients with breast cancer.  The Generex breast cancer vaccine was develop in conjunction with research conducted with Merck (NYSE: MRK). Together Scientus and Generex plan to deliver Scientus’s proprietary THC and CBD extractions via Generex’s RapdMist buccal mucosa delivery technology.  In other words, a medicinal THC and CBD delivered a spray in your mouth.

Generex is currently a quiet giant of a pharmaceutical company that most people probably are not yet aware even exists.  Do a little research and you will find Generex is loaded with proprietary, intellectual property protected pharmaceutical technology.  Given its recent FDA trials announcement and today’s partnership with Scientus, Generex is likely ready to no longer be quiet about its giant-hood.

Do a little more research and you will find the Generex has a pending 20:1 dividend coming soon. With just over one million shares currently issued and out, the dividend will take the issued and out just over 21 million with the holders of the roughly one million shares each getting 20 more shares for every share they own on the ex-dividend date.  And no, the ex-dividend date has not yet been set, but looks to be coming soon.

At a $10 million market capitalization, given the market capitalization of GW Pharmaceuticals (GWPH) at $4 billion, not to mention the $100 million market capitalization of delinquent filer Cannabis Science (OTC: CBIS), GNBT seems extraordinarily undervalued.  With GNBT’s IP portfolio, the current less than $10 PPS deserves to at least hold post the 20:1 dividend giving an investment now a potential 2000% ROI.  Even if the PPS were to remain at its currentl level, that will still just be a $200 million market capitalization.  The GNBT market cap likely has potential beyond $200 million giving a $10 per share investment now even a more dramatic upside opportunity.

Learn more about Generex at http://www.generex.com/

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. 

Source: www.nextbigticker.com

 

 

PURA – Puration Inc NEW BUY ALERT After $100 Million 30 Day Trading Volume: Analyst Research $0.25 PPS Target Confirmation

New York, NY – October 29, 2018 - Puration, Inc. (PURA) closed trading on Friday above $0.12 after two days of buy-side trading volume.  AmericanBulls.com has issued a BUY rating based on candle stick analysis.  The stock has traded approximately $100 million is the last 30 days.  On September 16th, the PPS was $0.03 and on October 16th, the PPS reached a high of $0.25.  After the PPS hit the $0.025 Target PPS previously issued by Goldman Small Cap Research, Goldman subsequently issued a TRADE ALERT indicating the pull-back was a buying opportunity and that the PPS was anticipated to return to its previous $0.25 target PPS. 

Screen Shot 2018-10-29 at 6.26.40 AM.png

“Our system’s recommendation today is to BUY. The BULLISH HARAMI pattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.1180, and our valid average buying price stands now at 0.1182.

“The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. The market is telling you about a new profit. Do not miss this bullish opportunity.”

Puration was recently featured in the Oracale Dispatch, Wall Street Daily:

Oracle logo-od-300x71.png

“One of the most explosive plays in the cannabis-related space that remains well above its September levels is Puration Inc (OTCMKTS:PURA). The stock is a player in the cannabis-infused beverage space that recently disclosed some talks with major beverage companies, including a player in the Coca-Cola corporate food chain. That theme has further developed, and now the company just announced that its EVERx CBD Sports Water will be available for purchase online soon.

According to the release, “The online shopping site will include an option to purchase EVERx with cryptocurrency. The online sales will augment the current availability of EVERx at retail outlets. The company recently announced updating the EVERx packaging to include a new EVERx logo and labels.” “

Top marijuana stocks to watch now – Tilray (TLRY), Canopy Growth (CGC) and Aurora Cannabis (ACB).

Learn more about Puration’s stock performance potential at Goldman Small Cap Research, and learn more about Puration’s overall business on the company’s website.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

 

Triple Zero Cannabis Plays With 1000% ROI Potential: KALY NOUV EVSV USMJ

New York, NY – October 26, 2018 – The cannabis sector is a red-hot sector on the heels of the first G-7 nation, Canada, implementing its legal recreational marijuana laws last week and with the United States on the verge of taking hemp off the DEA schedule 1 list in the pending passage of the 2018 Farm Bill.  Triple zero priced stocks ($0.0001 - $0.0009) can rapidly deliver a high rate of return on investment when a company priced in this range closes on a business development initiative showing the slightest prospect that the company might just edge a little closer toward long-term success.  Combine triple zero priced stocks with red-hot cannabis sector opportunities and you increase the likelihood that a $0.0001 PPS could go to $0.01 delivery a 2000% ROI.  Here are some promising cannabis sector companies with triple zero priced stocks that have appealing cannabis business plans and the prospects to be 1000% ROI opportunities.

Kali, Inc. (USOTC: KALY) ($0.0008) – KALY just announced an LOI to acquire a patented cannabis extraction business.  The stock price jumped on high volume from $0.0002 to $0.002 and then retraced back to its current $0.0008 level now.  If KALY caries through and closes the patented cannabis extraction acquisition, its quite possible the PPS could go above a penny on short notice. 

Enviro-Serv, Inc. (USOTC: EVSV) ($0.0002) – EVSV has an interesting background actually making money in pest control and fertilizer.  Well management saw the legalization of hemp farming on the 2018 farm bill and wisely decided to get into the market.  It’s only a matter of time before EVSV announces there first hemp farming contract likely igniting a rapid PPS climb into the double zero range delivering a 1000% ROI.

Nouveau Life Pharmaceuticals (USOTC: NOUV) ($0.0002) - NOUV has recently acquired a cannabis cultivation operation from cannabis industry juggernaut Puration, Inc. (USOTC: PURA). The company is issuing a stock dividend to the shareholders of PURA.  The dividend, set to be declared on the 15th of November, and the overall business relationship with PURA stands to potentially drive NOUV into the double digits between now and the 15th of November.

North American Cannabis Holdings (USOTC: USMJ) ($0.0003) – USMJ is a sub penny institution in the cannabis sector.  The company has incubated and produced multiple cannabis industry enterprises.  USMJ, in fact, spun off the operation that is now PURA and USMJ is getting ready to spin-off another operation – the AmeriCanna Cafe which has already announced a contract with a Denver Restaurant chain [a subsidiary of West Coast Venture (OTCQB: WCVC)] to bring the cannabis themed restaurant to Colorado.  USMJ has delivered multiple $0.0001 runs to $0.001 in its long cannabis sector history and is likely deliver another one in conjunction with the latest spin-off and dividend.  Management has shown no interest in reverse splits and seems content with working in the sub penny range continuing to incubate new cannabis sector enterprises and giving shareholders the opportunity to enjoy one triple zero to double zero run after another.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

ALYI - Alternet Systems BUY ALERT Following Hemp Strategy Feature In Forbes

New York, NY – October 26, 2018 – Alternet Systems, Inc. (USOTC: ALYI) is rated a BUY today by AmericanBulls.com.  The BUY rating followings the market response to Alternet’s recent move into hemp energy kicked off by the engagement of Clarkson University Professor David Mitlin, a leading expert in electrochemistry and a pioneer in the use of hemp as a clean, renewable energy in the form of a supercapacitor.  Alternet announced yesterday David Mitlin being featured in a recent Forbes publication on the industrial applications of Hemp titled The Age Of Hemp: Global Advanced Industrial Applications.

Screen Shot 2018-10-26 at 7.35.51 AM.png

AmericanBulls.com on ALYI

“Our system’s recommendation today is to BUY. The BULLISH PIERCING LINE pattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0080, and our valid average buying price stands now at 0.0081.

Let’s jump on our white horses and go for a bullish ride. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. The market is telling you about a new profit. Do not miss this bullish opportunity.” 

Goldman Small Cap Research For ALYI - Speculative-Buy and $0.09 Target PPS 

Goldman Small Cap Research recently issued an updated research report on ALYI. The report includes a 'speculative-buy' rating with a target price-per-share of $0.09. The report provides an in-depth overview and analysis of Alternet's new strategy, new orders, and upcoming milestones. To view the report, along with disclosures and disclaimers, visit https://www.alternetsystemsinc.com/research-rpt/ or http://www.GoldmanResearch.com.  Management indicates that the company will engage Goldman to issue another update in the event the company reaches its first million in revenue by year end, 2018.

Other cannabis sector companies in the news include Puation, Inc. (PURA), Rocky Mount High Brands, Inc. (RMHB), and North American Cannabis Holdings, Inc. (USMJ).

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

 

 

 

EVSV Rated VERY BULLISH By BullishInvestor.com On Cannabis News

New York, NY - October 25, 2018 - Enviro-Serv Inc. (USOTC: EVSV) is rated today by yet another stock analyst firm as VERY BULLISH. Yesterday, the trading volume reached a record high of over 100 million shares. The company recently reported developments in the $10.6 billion hemp farming sector in conjunction with the anticipated nationwide legalization of hemp farming contemplated as part of the 2018 Farm Bill.  The EVSV could rocket from the low triple zero price range into the double zero range delivery a 1000% ROI.

Screen Shot 2018-10-25 at 8.44.03 AM.png

BullishInvestor.com reported today:

“The stock price direction for the day for EVSV is UP. The stock is experiencing a strong uptrend as of late, with an increase of more than 15 percent in the last five days. Based on BullishInvestor.com’s proprietary algorithms, EVSV is currently signaling VERY BULLISH.

…Overall the technical indicators are signaling a bullish reading for EVSV. As such, it may be a wise decision to consider EVSV at these price levels.

Since the stock is currently rated VERY BULLISH, investors are encouraged to take a closer look at this stock from a technical analysis perspective.”

https://www.otcmarkets.com/stock/EVSV/overview

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

EVSV PPS and VOL BREAKOUT On Hemp News– Rated VERY BULLISH – 300% Near Term Potential

New York, NY – October 24, 2018 – Enviro-Serv Inc. (USOTC: EVSV) breakout yesterday after reporting developments in the $10.6 billion hemp farming sector in light of the anticipated nationwide legalization of hemp farming contemplated as part of the 2018 Farm Bill.  Trading volume and PPS jumped with 65 million shares of buying closing at a PPS of $0.0003.  Stock Tech Analysis (stockta.com) has rated EVSV as VERY BULLISH based on candlestick analysis.

Screen Shot 2018-10-24 at 8.31.19 AM.png

EVSV’s entry into the red hot cannabis sector could see momentum carry the PPS in the double zero range delivering a near-term 300% ROI.

Other hot cannabis sector stocks include Pot Networks (POTN), North American Cannabis Holdings (USMJ) and Nouveau Life Pharmaceuticals (NOUV).

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

 

Source: www.nextbigticker.com

 

KALY PPS Breaks Out with Record Volume on Cannabis News Heading To 300% Potential Gain

New York, NY – October 18, 2018 Kali, Inc. (USOTC: KALY) trading reached record high volume on Friday with over 600 million shares traded.  The price per share (PPS) jumped up 100% to close at $0.0006.  With a 52-week high of $0.0021, the PPS could still climb over another 300% back to its 52 week high now that the company has entered the red hot cannabis sector.

Kali, Inc. (USOTC: KALY) announced a letter of intent (LOI) on Friday, October 19th, 2018 to acquire NCM Biotech.  The Friday press release reported that NCM Biotech has developed a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”  NCM’s process has been engaged in a number of medical and pharmaceutical research and development projects in addition to being licensed to Puration, Inc. (USOTC: PURA) for commercial applications.

Screen Shot 2018-10-22 at 8.20.56 AM.png

Press Release Highlights: 

“I have received doctor feedback from more than one of our research initiatives that extracts coming from NCM Biotech’s patented process are superior in purity and quality to any other available cannabis extracts,” said Frederick Ferri, CEO and Founder of NCM Biotech. “Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical [GWPRF] products and candidate products. 

The acquisition plans contemplate NCM management assuming the senior management positions at Kali in conjunction with the planned acquisition.

NCM Biotech’s medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children;  Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs.

Kali plans to pursue pharmaceutical and other commercial applications of its patented extraction process building on the success of its current research projects and its success with Puration.

Kali maintains assets and operations today in the marina management business of which it plans to divest in conjunction with the planned acquisition of NCM Biotech.

Learn more about NCM Biotech at https://www.ncmbiotech.com/

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

PURA Hits $0.025 Analyst Trgt PPS And Snaps Back To Give Great Entry Point With Big Upside

New York, NY – October 18, 2018 - Puration, Inc. (PURA) has seen a tremendous increase in price-per-share and trading volume in the last two weeks.  Goldman Small Cap Research issued a speculative BUY and $0.025 PPS Target on October 10th.  The PURA PPS hit $0.25 earlier this week and snapped back.  Goldman says, “with the wind at its back current prices appear to be a great entry point with big upside ahead.”

Screen Shot 2018-10-18 at 5.49.20 AM.png

 PURA Get’s Look From Coca-Cola

In addition to reporting 600% growth, a spinoff and corresponding upcoming dividend, the company’s EVERx CBD Sports Water has attracted the interest of Coca-Cola.

Learn more about Puration’s stock performance potential at Goldman Small Cap Research, and learn more about Puration’s overall business on the company’s website.

Other active Companies from around the market with current developments this week include: Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON), Medical Marijuana Inc. (OTC:MJNA), PotNetwork Holdings Inc. (OTC:POTN), MedMen Enterprises Inc. (OTC:MMNFF) (CSE:MMEN).

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

 

Source: www.nextbigticker.com